To determine if our cultured DCs could be engineered for therapeutic delivery we tested human brain-derived neurotrophic factor (hBDNF) as a candidate extracellular cargo, as post-injury delivery of hBDNF protects in stroke models [20], [21]; this effect occurs extracellularly via TrkB receptor binding [22]. The gene discussed is BDNF; the disease is stroke disorder.